Komipharm International Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 271.02 million compared to KRW 558.85 million a year ago. Net loss was KRW 826.55 million compared to KRW 97.85 million a year ago.

Basic loss per share from continuing operations was KRW 11.8182 compared to KRW 1.8182 a year ago. Diluted loss per share from continuing operations was KRW 11.8182 compared to KRW 1.8182 a year ago. Basic loss per share was KRW 11.8182 compared to KRW 1.8182 a year ago.